PROTEIN STRUCTURE BASED DESIGN OF ANTI-HIV DRUGS

Information

• Research Project
• 3096343

• ApplicationId

  3096343

• Core Project Number

  P01GM039599

• Full Project Number

  5P01GM039599-02

• Serial Number

  39599

• FOA Number

  RFA-NI-H8-01

• Sub Project Id

• Project Start Date

  9/1/1987 - 37 years ago

• Project End Date

  8/31/1992 - 32 years ago

• Program Officer Name

• Budget Start Date

  9/1/1988 - 36 years ago

• Budget End Date

  8/31/1989 - 35 years ago

• Fiscal Year

  1988

• Support Year

  2

• Suffix

• Award Notice Date

  8/12/1988 - 36 years ago

Organizations

• Agouron Pharmaceuticals, Inc.

Specific Aims 1. Express HTLV-III encoded wild-type and mutant proteins in E. coli or eukaryotic cells using recombinant DNA clones provided by Drs. Haseltine and Sodrowski at the Dana Farber Cancer Institute (DFCI). This may require additional modification of the encoding DNA sequences. 2. Prepare large scale cultures (both bacterial and eukaryotic) expression proteins of interest. 3. Purify large amounts of expressed proteins in a biologically active form. Renaturation of purified proteins to an active configuration may be required. 4. Provide expressed protein preparations to scientists from DFCI for testing of biological activity. 5. Provide expressed protein preparations to scientists from Agouron Pharmaceuticals, Inc. for crystallography.

IC Name

• Activity

  P01

• Administering IC

  GM

• Application Type

  5

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

• Ed Inst. Type

• Funding ICs

• Funding Mechanism

• Study Section

  SRC

• Study Section Name

• Organization Name

  AGOURON PHARMACEUTICALS, INC.

• Organization Department

• Organization DUNS

• Organization City

  SAN DIEGO

• Organization State

  CA

• Organization Country

  UNITED STATES

• Organization Zip Code

  921211122

• Organization District

  UNITED STATES